**Background of ANPRB Antibody**
The ANPRB antibody targets the atrial natriuretic peptide receptor B (ANPRB), also known as natriuretic peptide receptor B (NPR-B) or NPR2. a transmembrane guanylyl cyclase receptor primarily activated by C-type natriuretic peptide (CNP). NPR-B plays a critical role in regulating cardiovascular homeostasis, bone growth, and cellular proliferation through the production of cyclic guanosine monophosphate (cGMP), which mediates downstream signaling pathways.
NPR-B is structurally characterized by an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular guanylyl cyclase domain. Dysregulation of NPR-B signaling is linked to pathologies such as skeletal dysplasia (e.g., short-limbed dwarfism), hypertension, and heart failure. ANPRB antibodies are essential tools in biomedical research for detecting NPR-B expression, studying its physiological roles, and exploring its involvement in disease mechanisms.
These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to assess receptor localization, expression levels, and activation status in tissues or cell lines. Research utilizing ANPRB antibodies has advanced understanding of CNP/NPR-B signaling in vascular remodeling, endochondral ossification, and cancer progression. Their application also supports drug discovery efforts aimed at modulating NPR-B activity for therapeutic interventions.
Overall, ANPRB antibodies are pivotal in elucidating the complex roles of NPR-B in health and disease, bridging molecular insights with clinical relevance.